Thorne SH - Search Results

1

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

Thorne SH, Hermiston T, Kirn D. Thorne SH, et al. Semin Oncol. 2005 Dec;32(6):537-48. doi: 10.1053/j.seminoncol.2005.09.007. Semin Oncol. 2005. PMID: 16338419 Review.

2

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH. Huang B, et al. Among authors: thorne sh. Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26. Gene Ther. 2011. PMID: 20739958

3

Combining immune cell and viral therapy for the treatment of cancer.

Thorne SH, Contag CH. Thorne SH, et al. Cell Mol Life Sci. 2007 Jun;64(12):1449-51. doi: 10.1007/s00018-007-6550-z. Cell Mol Life Sci. 2007. PMID: 17404689 Review.

4

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.

Thorne SH, Contag CH. Thorne SH, et al. Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356814 Review.

5

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Thorne SH, et al. Mol Ther. 2006 May;13(5):938-46. doi: 10.1016/j.ymthe.2005.12.010. Epub 2006 Feb 8. Mol Ther. 2006. PMID: 16469543

6

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Kirn DH, et al. Among authors: thorne sh. Cancer Res. 2008 Apr 1;68(7):2071-5. doi: 10.1158/0008-5472.CAN-07-6515. Cancer Res. 2008. PMID: 18381410

7

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH. Thorne SH, et al. Curr Gene Ther. 2005 Aug;5(4):429-43. doi: 10.2174/1566523054546215. Curr Gene Ther. 2005. PMID: 16101516 Review.

8

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL. Zeh HJ, et al. Among authors: thorne sh. Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8. Mol Ther. 2015. PMID: 25292189 Free PMC article. Clinical Trial.

9

Oncolytic adenoviruses for cancer gene therapy.

Liu TC, Thorne SH, Kirn DH. Liu TC, et al. Among authors: thorne sh. Methods Mol Biol. 2008;433:243-58. doi: 10.1007/978-1-59745-237-3_15. Methods Mol Biol. 2008. PMID: 18679628

10

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Guo ZS, Thorne SH, Bartlett DL. Guo ZS, et al. Among authors: thorne sh. Biochim Biophys Acta. 2008 Apr;1785(2):217-31. doi: 10.1016/j.bbcan.2008.02.001. Epub 2008 Feb 15. Biochim Biophys Acta. 2008. PMID: 18328829 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results